查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1612120

同种异体细胞治疗市场：按类型、应用和最终用途 - 2025-2030 年全球预测

Allogeneic Cell Therapy Market by Type, Application, End-Use - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年同种异体细胞治疗市值为20.4亿美元，预计2024年将达23.1亿美元，复合年增长率为13.90%，到2030年将达到50.8亿美元。

同种异体细胞疗法涉及使用来自捐赠者的细胞来治疗各种疾病和病症，并且与利用患者自身细胞的自体细胞疗法不同。这种需求源于随时获得治疗方法和标准化细胞产品的可能性，以解决传统方法通常无法治疗的癌症和遗传性疾病等严重。临床上，该疗法已应用于血液学、肿瘤学、心臟病学和再生医学，其中移植和组织再生是主要的最终应用领域。主要成长动力包括慢性病盛行率上升、研发投资增加、细胞技术进步。机会包括扩大罕见疾病的应用、改善商业规模的製造以及製定强有力的法规结构以促进市场准入。抓住这些机会的研究包括促进生物製药公司、研究机构和政府机构之间的合作，以简化开发和监管流程。然而，也存在重大限制，例如治疗成本高、製造复杂性、免疫排斥的可能性以及围绕细胞采购和操作的伦理问题，这些可能会阻碍市场成长。挑战包括监管障碍、严格的品管措施以及确保移植的适用性。儘管如此，在基因编辑技术、增强冷冻保存技术和抑制免疫反应的通用供体细胞株等领域仍存在创新机会。此外，开发更具成本效益和可扩展的製造解决方案可以显着提高市场渗透率。该市场的特点是技术进步迅速、竞争激烈、高度关注临床疗效和安全性。整体而言，市场成功之路需要策略创新、协作以及积极主动的方法来克服道德和监管挑战。

主要市场统计
基准年[2023] 20.4亿美元
预计年份 [2024] 23.1亿美元
预测年份 [2030] 50.8亿美元
复合年增长率（%） 13.90%

市场动态：针对快速发展的同种异体细胞治疗市场揭示的关键市场见解

同种异体细胞治疗市场正因供需的动态交互作用而转变。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 癌症、自体免疫疾病和心血管疾病的增加
    • 有利的政府政策和细胞治疗研究经费的增加
  • 市场限制因素
    • 同种异体细胞疗法的开发和管理的复杂法规环境
  • 市场机会
    • 个性化同种异体细胞治疗解决方案的开发
    • 开拓神经退化性疾病和心臟疾病的新治疗方法
  • 市场挑战
    • 免疫排斥和相容性问题

波特五力：驾驭同种异体细胞治疗市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解异体细胞治疗市场的外部影响

外部宏观环境因素在塑造同种异体细胞治疗市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解同种异体细胞治疗市场的竞争格局

同种异体细胞治疗市场的详细市场占有率分析可以对供应商的表现进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV定位矩阵同种异体细胞治疗市场供应商绩效评估

FPNV定位矩阵是评估同种异体细胞治疗市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议描绘了同种异体细胞治疗市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，同种异体细胞治疗市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 癌症、自体免疫疾病和心血管疾病的发生率增加
      • 有利的政府政策和增加细胞治疗方法研究资金
    • 抑制因素
      • 同种异体细胞疗法开发和管理的复杂法规环境
    • 机会
      • 开发个人化同种异体细胞治疗解决方案
      • 探索神经退化性疾病疾病和心臟病的新治疗方法
    • 任务
      • 免疫排斥和相容性问题
  • 市场区隔分析
    • 类型：由于发炎和免疫调节特性，间质干细胞疗法的采用增加
    • 应用：彻底改变同种异体细胞疗法在器官移植治疗和改善中的作用
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章同种异体细胞治疗市场：依类型

  • 嵌合体抗原受体T细胞疗法
  • 造血干细胞移植
  • 诱导性多功能干细胞治疗
  • 间质干细胞治疗

第七章同种异体细胞治疗市场：依应用分类

  • 血液疾病
  • 肿瘤学
  • 再生医学
  • 固态器官移植

第八章同种异体细胞治疗市场：依最终用途

  • 生物技术和製药公司
  • 医院/诊所
  • 调查机构

第九章美洲同种异体细胞治疗市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太同种异体细胞治疗市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章欧洲、中东和非洲同种异体细胞治疗市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • Getinge 与 Sellev 之间的策略合作伙伴关係将彻底改变製造业。
    • 开创性协议将促进全球获得 StemCyte 突破性的脐带血衍生细胞疗法
    • FDA核准Gamida Cell 的 Omisirge 疗法作为血癌治疗的突破性进展
  • 战略分析和建议

公司名单

  • Abeona Therapeutics Inc.
  • AlloSource
  • Anterogen.Co., Ltd.
  • Atara Biotherapeutics by FUJIFILM Diosynth Biotechnologies
  • Athersys Inc.
  • Biorestorative Therapies Inc.
  • Biosolution Co., Ltd.
  • Bloodworks Northwest
  • Brainstorm Cell Limited
  • Caribou Biosciences
  • Fate Therapeutics
  • Gamida Cell
  • Hope Biosciences
  • JCR Pharmaceuticals Co., Ltd.
  • Mallinckrodt Pharmaceuticals
  • MEDIPOST Co., Ltd.
  • Mesoblast Ltd.
  • NuVasive Inc. by Globus Medical
  • RTI Surgical
  • Smith+Nephew PLC
  • Stempeutics Research Pvt. Ltd.
  • Sumitomo Pharma Co., Ltd.
  • Takeda Pharmaceutical Company Limited
  • Tego Science Inc.
  • ViaCyte Inc. by Vertex Pharmaceuticals
Product Code: MRR-CA100284D019

The Allogeneic Cell Therapy Market was valued at USD 2.04 billion in 2023, expected to reach USD 2.31 billion in 2024, and is projected to grow at a CAGR of 13.90%, to USD 5.08 billion by 2030.

Allogeneic cell therapy involves the use of cells from a donor to treat various diseases and medical conditions, making it distinct from autologous therapies that utilize a patient's own cells. Its necessity stems from the potential to provide immediate availability of treatment and standardized cell products, addressing severe diseases, such as cancers and genetic disorders, which are often untreatable by conventional means. Clinically, this therapy has found applications in hematology, oncology, cardiology, and regenerative medicine, with transplant and tissue regeneration being primary end-use areas. Key growth drivers include rising prevalence of chronic diseases, increasing investments in research and development, and advances in cell-based technologies. Opportunities lie in expanding applications to rare diseases, commercial-scale manufacturing improvements, and developing robust regulatory frameworks that expedite market access. Recommendations for seizing these opportunities include fostering collaborations between biopharmaceutical companies, research institutes, and governmental bodies to streamline development and regulatory processes. However, substantial limitations exist, such as the high cost of therapy, complexity of production, potential for immune rejection, and ethical concerns around cell sourcing and manipulation, which could impede market growth. Challenges include regulatory hurdles, stringent quality control measures, and ensuring compatibility in transplantation. Still, innovation potentials abound in areas such as gene-editing technologies, enhanced cryopreservation techniques, and universal donor cell lines to reduce immune responses. Furthermore, the development of more cost-effective and scalable manufacturing solutions can significantly boost market penetration. The market is characterized by rapid technological advancements, competitive tension, and a strong focus on clinical efficacy and safety. Overall, the path to market success requires strategic innovations, collaboration, and a proactive approach to overcoming ethical and regulatory challenges.

KEY MARKET STATISTICS
Base Year [2023] USD 2.04 billion
Estimated Year [2024] USD 2.31 billion
Forecast Year [2030] USD 5.08 billion
CAGR (%) 13.90%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Allogeneic Cell Therapy Market

The Allogeneic Cell Therapy Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing incidences of cancers, autoimmune diseases, and cardiovascular conditions
    • Favorable government policies and increased funding for research in cell-based therapies
  • Market Restraints
    • Complex regulatory environment for development and administration of allogeneic cell therapies
  • Market Opportunities
    • Development of personalized allogeneic cell therapy solutions
    • Exploration into the new treatment avenues in neurodegenerative diseases and cardiac diseases
  • Market Challenges
    • Immune rejection and compatibility issues

Porter's Five Forces: A Strategic Tool for Navigating the Allogeneic Cell Therapy Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Allogeneic Cell Therapy Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Allogeneic Cell Therapy Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Allogeneic Cell Therapy Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Allogeneic Cell Therapy Market

A detailed market share analysis in the Allogeneic Cell Therapy Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Allogeneic Cell Therapy Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Allogeneic Cell Therapy Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Allogeneic Cell Therapy Market

A strategic analysis of the Allogeneic Cell Therapy Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Allogeneic Cell Therapy Market, highlighting leading vendors and their innovative profiles. These include Abeona Therapeutics Inc., AlloSource, Anterogen.Co., Ltd., Atara Biotherapeutics by FUJIFILM Diosynth Biotechnologies, Athersys Inc., Biorestorative Therapies Inc., Biosolution Co., Ltd., Bloodworks Northwest, Brainstorm Cell Limited, Caribou Biosciences, Fate Therapeutics, Gamida Cell, Hope Biosciences, JCR Pharmaceuticals Co., Ltd., Mallinckrodt Pharmaceuticals, MEDIPOST Co., Ltd., Mesoblast Ltd., NuVasive Inc. by Globus Medical, RTI Surgical, Smith+Nephew PLC, Stempeutics Research Pvt. Ltd., Sumitomo Pharma Co., Ltd., Takeda Pharmaceutical Company Limited, Tego Science Inc., and ViaCyte Inc. by Vertex Pharmaceuticals.

Market Segmentation & Coverage

This research report categorizes the Allogeneic Cell Therapy Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Chimeric Antigen Receptor T Cell Therapy, Hematopoietic Stem Cell Transplantation, Induced Pluripotent Stem Cell Therapy, and Mesenchymal Stem Cell Therapy.
  • Based on Application, market is studied across Hematological Disorders, Oncology, Regenerative Medicine, and Solid Organ Transplantation.
  • Based on End-Use, market is studied across Biotechnology & Pharmaceutical Companies, Hospitals & Clinics, and Research Institutes.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing incidences of cancers, autoimmune diseases, and cardiovascular conditions
      • 5.1.1.2. Favorable government policies and increased funding for research in cell-based therapies
    • 5.1.2. Restraints
      • 5.1.2.1. Complex regulatory environment for development and administration of allogeneic cell therapies
    • 5.1.3. Opportunities
      • 5.1.3.1. Development of personalized allogeneic cell therapy solutions
      • 5.1.3.2. Exploration into the new treatment avenues in neurodegenerative diseases and cardiac diseases
    • 5.1.4. Challenges
      • 5.1.4.1. Immune rejection and compatibility issues
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Type: Growing adoption of mesenchymal stem cell therapy due to anti-inflammatory and immunomodulatory properties
    • 5.2.2. Application: Revolutionizing allogeneic cell therapy's role in treating and improving organ transplantation procedures
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Allogeneic Cell Therapy Market, by Type

  • 6.1. Introduction
  • 6.2. Chimeric Antigen Receptor T Cell Therapy
  • 6.3. Hematopoietic Stem Cell Transplantation
  • 6.4. Induced Pluripotent Stem Cell Therapy
  • 6.5. Mesenchymal Stem Cell Therapy

7. Allogeneic Cell Therapy Market, by Application

  • 7.1. Introduction
  • 7.2. Hematological Disorders
  • 7.3. Oncology
  • 7.4. Regenerative Medicine
  • 7.5. Solid Organ Transplantation

8. Allogeneic Cell Therapy Market, by End-Use

  • 8.1. Introduction
  • 8.2. Biotechnology & Pharmaceutical Companies
  • 8.3. Hospitals & Clinics
  • 8.4. Research Institutes

9. Americas Allogeneic Cell Therapy Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Allogeneic Cell Therapy Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Allogeneic Cell Therapy Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. Getinge's Strategic Partnership with CellRev to Revolutionize Allogeneic Cell Therapy Manufacturing
    • 12.3.2. StemCyte's Pioneering Agreement for Advancing Worldwide Access to Groundbreaking Cord Blood-Derived Cell Therapies
    • 12.3.3. FDA Approval of Gamida Cell's Omisirge Therapy as Transformative Leap in Hematological Cancer Treatment
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abeona Therapeutics Inc.
  • 2. AlloSource
  • 3. Anterogen.Co., Ltd.
  • 4. Atara Biotherapeutics by FUJIFILM Diosynth Biotechnologies
  • 5. Athersys Inc.
  • 6. Biorestorative Therapies Inc.
  • 7. Biosolution Co., Ltd.
  • 8. Bloodworks Northwest
  • 9. Brainstorm Cell Limited
  • 10. Caribou Biosciences
  • 11. Fate Therapeutics
  • 12. Gamida Cell
  • 13. Hope Biosciences
  • 14. JCR Pharmaceuticals Co., Ltd.
  • 15. Mallinckrodt Pharmaceuticals
  • 16. MEDIPOST Co., Ltd.
  • 17. Mesoblast Ltd.
  • 18. NuVasive Inc. by Globus Medical
  • 19. RTI Surgical
  • 20. Smith+Nephew PLC
  • 21. Stempeutics Research Pvt. Ltd.
  • 22. Sumitomo Pharma Co., Ltd.
  • 23. Takeda Pharmaceutical Company Limited
  • 24. Tego Science Inc.
  • 25. ViaCyte Inc. by Vertex Pharmaceuticals

LIST OF FIGURES

  • FIGURE 1. ALLOGENEIC CELL THERAPY MARKET RESEARCH PROCESS
  • FIGURE 2. ALLOGENEIC CELL THERAPY MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS ALLOGENEIC CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS ALLOGENEIC CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES ALLOGENEIC CELL THERAPY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES ALLOGENEIC CELL THERAPY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC ALLOGENEIC CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC ALLOGENEIC CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ALLOGENEIC CELL THERAPY MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. ALLOGENEIC CELL THERAPY MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ALLOGENEIC CELL THERAPY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ALLOGENEIC CELL THERAPY MARKET DYNAMICS
  • TABLE 7. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANTATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY INDUCED PLURIPOTENT STEM CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY MESENCHYMAL STEM CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY HEMATOLOGICAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY REGENERATIVE MEDICINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY SOLID ORGAN TRANSPLANTATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY BIOTECHNOLOGY & PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS ALLOGENEIC CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. BRAZIL ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 31. CANADA ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. CANADA ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 33. CANADA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 34. MEXICO ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. MEXICO ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 36. MEXICO ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 39. UNITED STATES ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 40. UNITED STATES ALLOGENEIC CELL THERAPY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 43. ASIA-PACIFIC ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 44. ASIA-PACIFIC ALLOGENEIC CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 45. AUSTRALIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. AUSTRALIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 47. AUSTRALIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 48. CHINA ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. CHINA ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 50. CHINA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 51. INDIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. INDIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 53. INDIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 54. INDONESIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. INDONESIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 56. INDONESIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 57. JAPAN ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. JAPAN ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 59. JAPAN ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 60. MALAYSIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. MALAYSIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 62. MALAYSIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 63. PHILIPPINES ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. PHILIPPINES ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 65. PHILIPPINES ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 66. SINGAPORE ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. SINGAPORE ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 68. SINGAPORE ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 69. SOUTH KOREA ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. SOUTH KOREA ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 71. SOUTH KOREA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 72. TAIWAN ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. TAIWAN ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 74. TAIWAN ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 75. THAILAND ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. THAILAND ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 77. THAILAND ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 78. VIETNAM ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. VIETNAM ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 80. VIETNAM ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 85. DENMARK ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. DENMARK ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 87. DENMARK ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 88. EGYPT ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. EGYPT ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 90. EGYPT ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 91. FINLAND ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. FINLAND ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 93. FINLAND ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 94. FRANCE ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. FRANCE ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 96. FRANCE ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 97. GERMANY ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. GERMANY ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 99. GERMANY ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 100. ISRAEL ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. ISRAEL ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 102. ISRAEL ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 103. ITALY ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. ITALY ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 105. ITALY ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 106. NETHERLANDS ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. NETHERLANDS ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 108. NETHERLANDS ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 109. NIGERIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. NIGERIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 111. NIGERIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 112. NORWAY ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. NORWAY ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 114. NORWAY ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 115. POLAND ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. POLAND ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 117. POLAND ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 118. QATAR ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. QATAR ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 120. QATAR ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 121. RUSSIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. RUSSIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 123. RUSSIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 124. SAUDI ARABIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. SAUDI ARABIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 126. SAUDI ARABIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 129. SOUTH AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 130. SPAIN ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. SPAIN ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 132. SPAIN ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 133. SWEDEN ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. SWEDEN ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 135. SWEDEN ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 136. SWITZERLAND ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. SWITZERLAND ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 138. SWITZERLAND ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 139. TURKEY ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. TURKEY ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 141. TURKEY ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED ARAB EMIRATES ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED ARAB EMIRATES ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED ARAB EMIRATES ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED KINGDOM ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED KINGDOM ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 147. UNITED KINGDOM ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 148. ALLOGENEIC CELL THERAPY MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 149. ALLOGENEIC CELL THERAPY MARKET, FPNV POSITIONING MATRIX, 2023